<DOC>
	<DOCNO>NCT00601198</DOCNO>
	<brief_summary>The purpose study determine effect amifostine ( ETHYOL ) decrease rate severity nerve dysfunction neuropathy ( numbness tingle hand foot ) associate FOLFOX chemotherapy .</brief_summary>
	<brief_title>A Study Amifostine ( Ethyol ) Patients With Colorectal Cancer</brief_title>
	<detailed_description>In addition , study provide information subject colorectal cancer receive amifostine combination chemotherapy drug . This study also look frequency complication associate amifostine chemotherapy . The FOLFOX chemotherapy regimen consist three drug , 5-FU , leucovorin , oxaliplatin , give intravenously ( vein ) every 2 week without Avastin give combination chemotherapy . FOLFOX approve Food Drug Administration ( FDA ) treatment cancer colon rectum . Amifostine chemotherapy drug . It approve Food Drug Administration ( FDA ) prevent moderate severe dryness mouth cause radiation treatment head neck cancer , prevent kidney damage cause cisplatin chemotherapy treatment ovarian non-small cell lung cancer . Amifostine FDA approve use study therefore consider investigational .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Histologically cytologicallyproven adenocarcinoma colon rectum AJCC stage II , III IV Male female age great equal 18 year ECOG Performance Status ( PS ) : 02 Men woman reproductive potential must agree use effective method contraception treatment 6 month study treatment If female , pregnant lactating . Documentation negative serum HCG pregnancy test woman childbearing potential require within 7 day prior consider nonchildbearing potential In opinion investigator , patient must life expectancy least 6 month At time study enrollment , absolute granulocyte count ( AGC ) must great equal 1500/mm3 , platelet count must great equal 100,000/mm3 There must evidence adequate hepatic renal function . Bilirubin less equal UNL , Alkaline phosphatase less equal 2.5xULN , AST le equal 1.5xULN , Creatine le equal 1.5xULN Signed write informed consent obtain prior studyspecific screen procedure Any condition past medical history contraindicate treatment oxaliplatin 5FU , report approval label information Hypersensitivity study treatment ( amifostine , oxaliplatin 5FU ) ingredient Received investigational drug within 30 day begin treatment study drug Concomitant treatment investigational agent Received prior oxaliplatin cisplatin base chemotherapy History peripheral neuropathy concomitant treatment drugs/ingredients report potential activity prevent peripheral sensory neuropathy : carbamazepine , gabapentin , phenytoin , gluthathione , alphalipoic acid , celecoxib , venlafaxine , vitamin B1 ( thiamine ) , B6 ( pyridoxine ) , ginko biloba . Multivitamins dietary supplement allow . Uncontrolled intercurrent illness : e.g . high blood pressure , unstable angina , symptomatic congestive hear failure ( NY Heart Association Classification III IV ) , serious cardiac arrhythmia , diabetes , active infection Concurrent active cancer originate primary site colon rectum Presence symptom suggest brain/spinal cord metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Oxaliplatin-induced Neuropathy</keyword>
	<keyword>Colon rectum</keyword>
</DOC>